Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SUICIDE-PREVENTION EFFECTS ASSOCIATED WITH CLOZAPINE THERAPY IN SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER
Autore:
REID WH; MASON M; HOGAN T;
Indirizzi:
POB 4015 HORSESHOE BAY TX 78657 UNIV TEXAS,HLTH SCI CTR SAN ANTONIO TX 00000 NOVARTIS PHARMACEUT AG BASEL SWITZERLAND
Titolo Testata:
Psychiatric services
fascicolo: 8, volume: 49, anno: 1998,
pagine: 1029 - 1033
SICI:
1075-2730(1998)49:8<1029:SEAWCT>2.0.ZU;2-K
Fonte:
ISI
Lingua:
ENG
Soggetto:
RISK; MORTALITY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Physical, Chemical & Earth Sciences
Physical, Chemical & Earth Sciences
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
15
Recensione:
Indirizzi per estratti:
Citazione:
W.H. Reid et al., "SUICIDE-PREVENTION EFFECTS ASSOCIATED WITH CLOZAPINE THERAPY IN SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER", Psychiatric services, 49(8), 1998, pp. 1029-1033

Abstract

Objective and methods: Suicide is a significant cause of death among patients with schizophrenia and schizoaffective disorder, affecting some 10 to 15 percent of these patients. This study examined annual suicide rates over a two-year period (1993-1995) among more than 30,000 patients with schizophrenia and schizoaffective disorder who received services from the Texas Department of Mental Health and Mental Retardation and suicide rates over a six-year period (1991-1996) among a subgroup of patients treated with clozapine. Results: The annual suicide rate for all patients with schizophrenia and schizoaffective disorder was63.1 per 100,000 patients, approximately five times higher than in the general population. In contrast, only one suicide occurred in six years among patients treated with clozapine who were of similar diagnosis, age, and sex, for a suicide rate of about 12.7 per 100,000 patientsper year. This rate is similar to the 15.7 per 100,000 patients per year for all U.S. patients treated with clozapine, calculated from datareported as of June 1996 to the clozapine national registry system maintained by Novartis Pharmaceuticals Corporation, the U.S. manufacturer of clozapine. Conclusions: The study results suggest that clozapine therapy is associated with a reduced risk of suicide among patients with schizophrenia and schizoaffective disorder.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 27/09/20 alle ore 22:54:42